To include your compound in the COVID-19 Resource Center, submit it here.

Mateon reports interim Phase II/III data for Zybrestat in ovarian cancer

Mateon Therapeutics Inc. (OTCQX:MATN) reported data from a second scheduled interim analysis of the first 40 patients with platinum resistant ovarian cancer

Read the full 222 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE